For the full year 2024, the Company is reiterating its 2024 guidance and expects revenue to be at least $100 million with an Adjusted EBITDA of at least $11 million.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a Row
- OptimizeRx’s preliminary Q4 results support bullish thesis, says Roth MKM
- OptimizeRx initiated with an Outperform at JMP Securities
- OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET
- OptimizeRx cuts FY24 revenue view to at least $100M from at least $110M
